A traceable nanoplatform for enhanced chemo-photodynamic therapy by reducing oxygen consumption

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Tumor hypoxia significantly limits the efficacy of oxygen-dependent therapies like photodynamic therapy (PDT) and chemotherapy.
• Developing strategies to overcome tumor hypoxia is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To design a traceable nanoplatform (DOX/Met/BSA-HA-CDs) capable of reducing oxygen consumption to combat tumor hypoxia.
• To enhance the therapeutic efficiency of PDT and chemotherapy in hypoxic tumors using this novel system.

Main Methods:

• Fabrication of a multifunctional nanoplatform incorporating carbon dots (CDs), doxorubicin (DOX), and metformin (Met).
• Utilizing CDs for both PDT and in vivo traceable imaging.
• Investigating the controlled release of Met in the hypoxic tumor microenvironment.
• Assessing oxygen consumption reduction and therapeutic efficacy through ex vivo and in vivo studies.

Main Results:

• The DOX/Met/BSA-HA-CDs nanoplatform effectively reduced oxygen consumption in the tumor site.
• Metformin exhibited a faster release in hypoxic conditions, improving tumor oxygenation.
• In vivo synergistic treatment demonstrated considerably enhanced cancer therapeutic efficiency.
• The nanoplatform enabled traceable imaging to guide treatment.

Conclusions:

• The developed traceable nanoplatform successfully mitigates tumor hypoxia by reducing oxygen consumption.
• This approach significantly enhances the efficacy of combined PDT and chemotherapy.
• The system shows great potential for guiding cancer therapy and improving treatment outcomes in hypoxic tumors.